Slate Medicines Appoints Mark W. Hahn to Board of Directors

3 weeks ago 20

Exec-Edge

Thu, July 16, 2026 astatine 11:18 AM CDT 1 min read

By Daniella Parra

Slate Medicines, a backstage biotech institution processing caller treatments for migraine and different headache disorders, has appointed Mark W. Hahn to its Board of Directors, they said.

The institution said Hahn brings much than 25 years of beingness sciences enactment experience, including serving arsenic CFO of Verona Pharma, wherever helium helped usher the institution done Phase 3 trials, FDA approval, and the commercialized motorboat of Ohtuvayre earlier its $10 cardinal acquisition by Merck successful 2025.

The Cancer Therapy Strategy VERAXA Is Betting the Company On

"We are pleased to invited Mark to the Slate Medicines Board astatine specified a pivotal infinitesimal for the company," said Gregory Oakes, MBA, Chief Executive Officer of Slate Medicines. "His past of steering companies done defining financial, clinical and commercialized milestones, including transitions from backstage to public, will beryllium a tremendous plus arsenic Slate works to bring much-needed caller attraction options to migraine patients who stay underserved by existent therapies."